Understanding SARCLISA®

The Understanding SARCLISA® (isatuximab-irfc) booklet discusses a novel anti-CD38 monoclonal antibody that is approved for patients with relapsed and refractory myeloma. Sarclisa binds to myeloma cells to kill them directly, and also recruits other immune system cells to kill myeloma cells. 

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.